Ni-Chun Tsai
Overview
Explore the profile of Ni-Chun Tsai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Querfeld C, Palmer J, Han Z, Wu X, Yuan Y, Chen M, et al.
Blood Adv
. 2025 Feb;
PMID: 39951620
Selective targeting of the functionally exhausted malignant T cells in cutaneous T-cell lymphoma (CTCL) and distinct cells within the tumor microenvironment (TME) via PD1/PD-L1 blockade (durvalumab) may restore an anti-tumor...
2.
Zain J, Tsai N, Palmer J, Simpson J, Adhikarla V, Bading J, et al.
Blood Adv
. 2024 Jun;
8(18):4812-4822.
PMID: 38838232
Peripheral T-cell lymphomas (PTCLs) have a poor prognosis with current treatments. High-dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT) is used as a consolidation strategy after achieving clinical remission...
3.
Othman T, Koller P, Tsai N, Yang D, Pourhassan H, Agrawal V, et al.
Am J Hematol
. 2024 May;
99(9):1680-1690.
PMID: 38804599
Allogeneic hematopoietic cell transplantation (HCT) offers a potential cure in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); nonetheless, relapses are common and the major cause of mortality. One strategy to...
4.
Mei M, Tsai N, Palmer J, Armenian S, Chen R, Rosen S, et al.
Clin Lymphoma Myeloma Leuk
. 2024 May;
24(8):537-542.
PMID: 38693037
Introduction: Brentuximab vedotin (BV) is an antibody-drug conjugate that delivers monomethyl auristatin E (MMAE) to CD30+ cells and is safe and effective in relapsed/refractory (r/r) Hodgkin lymphoma (HL). Although most...
5.
Tinajero J, Ngo D, Zhang J, Tsai N, Aribi A, Aldoss I, et al.
Leuk Lymphoma
. 2024 Apr;
65(7):1020-1023.
PMID: 38635368
No abstract available.
6.
Lustberg M, Fan-Havard P, Wong F, Hill K, Phelps M, Herrera K, et al.
Breast Cancer Res Treat
. 2024 Jan;
205(1):61-73.
PMID: 38280052
Purpose: Aromatase inhibitor (AI) therapy reduces risk of recurrence and death for postmenopausal women with breast cancer (BC); however, AI-induced arthralgia (AIIA) can lead to discontinuation of treatment. Curcumin, a...
7.
Pullarkat V, Chen L, Palmer J, Zhang J, Synold T, Buettner R, et al.
Cancer
. 2023 Oct;
130(5):727-739.
PMID: 37897709
Background: This study evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of 8-chloro-adenosine (8-Cl-Ado) in patients with relapsed/refractory acute myeloid leukemia (AML). Methods: 8-Cl-Ado was administered daily for 5 days;...
8.
Amanam I, Yao J, Puing A, Tsai N, Samuels D, Ngo D, et al.
Cancer Med
. 2023 Apr;
12(10):11248-11253.
PMID: 37081733
Introduction: In November 2020, the FDA issued an emergency use authorization (EUA) for monoclonal antibody (mAb) therapy in patients with mild-to-moderate COVID-19 at high risk for disease progression. Methods: We...
9.
Kasparian S, Wei O, Tsai N, Palmer J, Pal S, Lyou Y, et al.
Oncologist
. 2023 Mar;
28(8):699-705.
PMID: 36888587
Background: Relugolix is the newest form of androgen deprivation therapy (ADT) approved for prostate cancer. However, as an oral drug, several real-world concerns exist, particularly medication compliance, safety with other...
10.
Agrawal V, Pourhassan H, Tsai N, Ngo D, Koller P, Al Malki M, et al.
Transplant Cell Ther
. 2023 Jan;
29(5):314-320.
PMID: 36682470
Sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication that can be observed after allogeneic hematopoietic cell transplantation (HCT). Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody-drug conjugate that has demonstrated...